Biodesix Q3 2026 Results: Net Loss of $8.03M, Loss Narrows
Biodesix, Inc. reported total assets of $93.9 million as of September 30, 2026, an increase from $87.5 million at the end of 2025, primarily driven by a rise in cash and cash equivalents to $28.4 million. The company continues to operate as a non-accelerated filer and smaller reporting company, with 11,088,511 shares of common stock outstanding as of October 30, 2026.
- Key figure
- Net loss $8.03M